Ginsenoside 20(S)‑Rg3 inhibits the Warburg effect through STAT3 pathways in ovarian cancer cells

Area of Science:

• Biochemistry
• Oncology
• Pharmacology

Background:

• The Warburg effect, or aerobic glycolysis, is a hallmark of cancer cell metabolism crucial for proliferation.
• The precise mechanisms underlying the Warburg effect and its regulation in cancer remain incompletely understood.
• Signal transducer and activator of transcription 3 (STAT3) signaling is implicated in cancer-associated metabolic alterations.

Purpose of the Study:

• To investigate the effect of ginsenoside 20(S)-Rg3 on the Warburg effect in ovarian cancer cells.
• To elucidate the molecular mechanisms by which 20(S)-Rg3 modulates cancer cell metabolism, focusing on the STAT3 pathway and key glycolytic enzymes.
• To evaluate the therapeutic potential of 20(S)-Rg3 in preclinical ovarian cancer models.

Main Methods:

• In vitro studies using ovarian cancer cell lines to assess glycolysis inhibition by 20(S)-Rg3.
• Analysis of key glycolytic enzymes, hexokinase 2 (HK2) and pyruvate kinase M2 (PKM2), and the p-STAT3 (Tyr705) signaling pathway.
• In vivo experiments using nude mouse xenograft models to evaluate the effect of 20(S)-Rg3 on tumor growth and HK2 expression.

Main Results:

• Ginsenoside 20(S)-Rg3 significantly inhibits glycolysis in ovarian cancer cells by regulating HK2 and PKM2.
• 20(S)-Rg3 downregulates p-STAT3 (Tyr705), thereby affecting HK2 expression.
• Overexpression of STAT3 attenuated the inhibitory effect of 20(S)-Rg3 on the Warburg effect.
• In vivo, 20(S)-Rg3 treatment repressed HK2 expression in ovarian cancer xenografts.

Conclusions:

• Ginsenoside 20(S)-Rg3 effectively inhibits the Warburg effect in ovarian cancer cells via the STAT3/HK2 pathway.
• The findings highlight 20(S)-Rg3 as a promising therapeutic candidate for ovarian cancer treatment.
• Targeting cancer metabolism with natural compounds like 20(S)-Rg3 offers a potential therapeutic strategy.